Marengo Presents Interim Phase 2 STARt-002 Results for First-in-Class Selective T-Cell Agonist Invikafusp Alfa Plus Sacituzumab Govitecan Across Two Metastatic Breast Cancer Cohorts in Oral Presentation at SITC 2026